General Information of Drug (ID: DMW7TZV)

Drug Name
Lenacapavir Drug Info
Synonyms
GS-6207; 2189684-45-3; N-[(1R)-1-[3-[4-Chloro-3-(cyclopropylsulfonylamino)-1-(2,2-difluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2R,4S)-9-(difluoromethyl)-5,5-difluoro-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus-1 infection 1C62 Approved [1]
Human immunodeficiency virus infection 1C62 Phase 2/3 [2]
Cross-matching ID
PubChem CID
138059678
TTD Drug ID
DMW7TZV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
F4co vaccine DM6UQNW Human immunodeficiency virus infection 1C62 Phase 2 [4]
Vacc-4x DMDAKZW Human immunodeficiency virus-1 infection 1C62 Phase 2 [5]
VH4004280 DMM5L3S Human immunodeficiency virus infection 1C62 Phase 1 [6]
VH4011499 DM1GSSM Human immunodeficiency virus infection 1C62 Phase 1 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Capsid p24 (HIV p24) TTTWS2G POL_HV1B1 Inhibitor [3]

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215973.
2 ClinicalTrials.gov (NCT04150068) Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Gilead Sciences.
4 EP patent application no. 2621528, Vaccine.
5 Clinical pipeline report, company report or official report of Bionor Pharma.
6 Clinical pipeline report, company report or official report of ViiV Healthcare